A Phase 1 Multicenter Open-Label Study of CB-010 a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Go Back to All Clinical Trials

A Phase 1 Multicenter Open-Label Study of CB-010 a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Non Hodgkin Lymphoma
Age: Between 18 Year(s) - 90 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Histologically confirmed aggressive B-NHL
2. Documented CD19+ disease
3. At least 2 weeks since prior systemic non-investigational therapy at the time of start of lymphodepletion

You may not be eligible for this study if the following are true:

1. History of prior therapy with an anti-CD19 targeting agent (Part A only)
2. Active acute or chronic GvHD requiring therapy
3. History of allogeneic stem cell transplantation

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies